Teclistamab, in combination with daratumumab, is in clinical development for the treatment of adults with relapsed or refractory multiple myeloma (MM) who have had previous treatment. MM is a form of cancer that occurs in immune cells found in bone marrow. The disease occurs due to uncontrolled duplication of these immune cells, known as plasma cells. In relapsed or refractory MM (RRMM), the patient has gone into complete or partial remission but then the disease has returned (‘relapsed’) or the patient stops responding to treatment (‘refractory’). Despite many different treatment options being available to patients with RRMM, many patients do not respond to treatment or the disease returns following treatment. Therefore, there is need to develop additional treatment options for these patients.
Teclistamab with daratumumab for previously treated relapsed or refractory multiple myeloma
Teclistamab, in combination with daratumumab, is in clinical development for the treatment of adults with relapsed or refractory multiple myeloma (MM) who have had previous treatment. MM is a form of cancer that occurs in immune cells found in bone marrow. The disease occurs due to uncontrolled duplication of these immune cells, known as plasma cells. In relapsed or refractory MM (RRMM), the patient has gone into complete or partial remission but then the disease has returned (‘relapsed’) or the patient stops responding to treatment (‘refractory’).
Indications:
Multiple myeloma (MM)
Therapeutic Areas:
Haematological Cancer and Lymphomas
Year:
2022